EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Oral Ibrexafungerp for Vulvovaginal Candidiasis Treatment: An Analysis of VANISH 303 and VANISH 306

Oluwatosin Goje, Ryan Sobel, Paul Nyirjesy, Steven R Goldstein, Mark Spitzer, Brooke Faught, Shelagh Larson, Thomas King, Nkechi E Azie, David Angulo, Jack D Sobel

Journal of Women's Health · 2023-02 · 32 (2) · 178-186

DOI: 10.1089/jwh.2022.0132 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Journal of Women's Health, online erschienen am 08.02.2023. Verfasst von Oluwatosin Goje und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Cleveland Clinic Foundation, Case Western Reserve University, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Candidiasis, Vulvovaginal. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ibrexafungerp is a novel antifungal treatment for acute vulvovaginal candidiasis (VVC). Using pooled data from two phase three studies (VANISH 303 and 306) in the treatment of acute VVC, this analysis sought to determine the effectiveness of ibrexafungerp in various patient subgroups that may impact outcomes. Materials and Methods: Data from VANISH 303 (NCT03734991) and VANISH 306 (NCT03987620) evaluating ibrexafungerp 300 mg twice daily (BID) for 1 day versus placebo, were pooled and analyzed to determine clinical cure rate, clinical improvement, and mycological cure at the test-of-cure visit (day 11 ± 3) and symptom resolution at the follow-up visit (day 25 ± 4) in the overall population. Patient subgroups analyzed included race, body mass index (BMI), baseline vulvovaginal signs and symptoms (VSS) score, and Candida species.

Results

At the test-of-cure visit, patients receiving ibrexafungerp, compared with those who received placebo, had significantly higher rates of clinical cure (56.9% [214/376 patients] vs. 35.7% [65/182 patients]), clinical improvement (68.4% [257/376 patients] vs. 45.1% [82/182 patients]), and mycological cure (54.0% [203/376 patients] vs. 24.2% [44/182 patients]; all p < 0.0001). At the follow-up visit, patients receiving ibrexafungerp had sustained responses with higher symptom resolution rates (66.8% [251/376 patients]) versus placebo (48.4% [88/182 patients]; p < 0.0001). Race, BMI, baseline VSS score (including VSS severity score 13–18), and Candida species infection did not adversely affect clinical cure rates. Safety analysis results were consistent with the individual studies.

Conclusions

Ibrexafungerp provides a safe and well-tolerated first-in-class fungicidal, 1-day oral treatment for patients with acute VVC, the first new therapy in >20 years. Clinical Trial Registration Number: NCT03734991.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Candidiasis, VulvovaginalFemaleHumansAntifungal AgentsFluconazoleGlycosidesTriterpenes

Stichwörter der Autor:innen

Candida albicansantifungalibrexafungerpplacebovulvovaginal candidiasis

Substanzen

Antifungal AgentsFluconazoleGlycosidesibrexafungerpTriterpenes

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Cleveland Clinic Foundation, Case Western Reserve University, Cleveland, Ohio, USA.
  • Department of Obstetrics and Gynecology, Jefferson Vulvovaginal Health Center, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Department of Obstetrics and Gynecology, NYU Grossman School of Medicine, New York, New York, USA.
  • Center for Colposcopy, New Hyde Park, New York, USA.
  • Department of Obstetrics and Gynecology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, New York, USA.
  • Women's Institute for Sexual Health, Division of Urology Associates, PC, Nashville, Tennessee, USA.

Zitieren

APA

Goje, O., Sobel, R., Nyirjesy, P., Goldstein, S. R., Spitzer, M., Faught, B., Larson, S., King, T., Azie, N. E., Angulo, D., & Sobel, J. D. (2023). Oral Ibrexafungerp for Vulvovaginal Candidiasis Treatment: An Analysis of VANISH 303 and VANISH 306. Journal of Women's Health, 32(2), 178-186. https://doi.org/10.1089/jwh.2022.0132

Vancouver

Goje O, Sobel R, Nyirjesy P, Goldstein SR, Spitzer M, Faught B, et al. Oral Ibrexafungerp for Vulvovaginal Candidiasis Treatment: An Analysis of VANISH 303 and VANISH 306. Journal of Women's Health. 2023;32(2):178-186. doi:10.1089/jwh.2022.0132

BibTeX
@article{Goje2023,
  author = {Goje, Oluwatosin and Sobel, Ryan and Nyirjesy, Paul and Goldstein, Steven R and Spitzer, Mark and Faught, Brooke and Larson, Shelagh and King, Thomas and Azie, Nkechi E and Angulo, David and Sobel, Jack D},
  title = {Oral Ibrexafungerp for Vulvovaginal Candidiasis Treatment: An Analysis of VANISH 303 and VANISH 306},
  journal = {Journal of Women's Health},
  year = {2023},
  volume = {32},
  number = {2},
  pages = {178--186},
  doi = {10.1089/jwh.2022.0132}
}
Kostenlos starten →